Radiopharmaceutical Production FDG Synthesis Chemistry STOP.
BERAC April 2004 Radiopharmaceutical Sub- committee Report.
9
BERAC April 2004 Radiopharmaceutical Sub- committee Report
-
Upload
meredith-rich -
Category
Documents
-
view
212 -
download
0
description
DOE BER Largely responsible for modern nuclear medicine – 99m Tc for cardiac, bone scanning, etc. –Many new probes and radiotracers for diagnosis and therapy –Patient care studies in the millions US and throughout the world Era of Molecular Imaging: Key molecules, sub- cellular proteinomics, gene expression, whole cell function
Transcript of BERAC April 2004 Radiopharmaceutical Sub- committee Report.
BERACApril 2004
Radiopharmaceutical Sub-committee Report
Charge from Director Office of Science
• “( in view of major recent opportunities) to reassess how BER support might best stimulate directions in radiopharmaceutical research that are most likely to find translation into routine medical practice.”
• Driven by concern for shortages– Key personnel, now and future– Optimized facilities and infrastructure
DOE BER
• Largely responsible for modern nuclear medicine– 99m Tc for cardiac, bone scanning, etc.– Many new probes and radiotracers for diagnosis and
therapy– Patient care studies in the millions US and throughout
the world• Era of Molecular Imaging: Key molecules, sub-
cellular proteinomics, gene expression, whole cell function
Imaging the process of stem cell repopulation of the bone marrow
Gene expression labeling at 8 days
Imaging Anatomy and Function PROSTATE CANCER
MRI MRSI
18FDG PET-CT 18FDG PET- CTMRI T2 BOLD
Why DOE• Essential infrastructure : physical sciences and
expertise– Cyclotrons/ radiochemistry facilities– Radiochemistry, Organic Synthetic Chemistry
Expertise, and biology relevant to modern imaging– Translates into unique facilities for molecular imaging
tool development• Correlative Programs can provide depth of
scientific expertise– Structural Biology– Nanotechnology– GTL
Recommendations of RDP Sub-committee
• Centers of Excellence• Training of Radiochemists and other
chemists in allied disciplines, such as structural biology, medicinal chemistry
• Collaboration and joint planning with NIH and other key governmental agencies
• Regulatory review with FDA to faciitate probe development
Progress
• Partnership with NIH– Agreement on common goals
• BERAC RDP Recc.s and NIH Road map– Collaboration
• Role definition: DOE physical chemical and biologic science; NIH translatIon into man
• NIBIB, exploring joint programs with respect to nuclear medicine centers of excellence for technology development and training
Next Phase
Detailed definition of “Centers of Excellence” and Training
programs
